Published in Oncologist on August 22, 2012
Chemotherapy of ovarian cancer in elderly patients. Cancer Biol Med (2015) 0.82
Big data and computational biology strategy for personalized prognosis. Oncotarget (2016) 0.79
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Cancer of the ovary. N Engl J Med (2004) 11.21
Cancer screening in elderly patients: a framework for individualized decision making. JAMA (2001) 9.79
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet (2009) 6.65
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 5.56
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol (2000) 4.48
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol (2011) 4.07
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77
Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol (2007) 3.75
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71
Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol (2002) 3.53
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol (2010) 3.46
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol (2002) 2.51
Management of cancer in the older person: a practical approach. Oncologist (2000) 2.50
Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst (1998) 2.36
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst (2003) 2.14
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol (2008) 2.11
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol (2000) 1.72
Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer (2010) 1.71
Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer (1993) 1.68
Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol (2005) 1.67
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol (2006) 1.65
Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol (2003) 1.61
Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol (2003) 1.55
Pharmaceutical management of ovarian cancer : current status. Drugs (2008) 1.52
Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol (2003) 1.48
Second-line treatment of ovarian cancer. Oncologist (2000) 1.45
International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer (2007) 1.44
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer (2010) 1.40
Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol (2002) 1.34
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer (2003) 1.23
Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol (2010) 1.21
The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol (2005) 1.21
Ovarian cancer. Survival and treatment differences by age. Cancer (1993) 1.15
How does older age influence oncologists' cancer management? Oncologist (2010) 1.10
Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists. Crit Rev Oncol Hematol (2006) 1.09
Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol (2010) 1.06
Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol (2003) 1.05
Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer (1993) 1.04
Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol (2005) 1.01
Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol (2010) 1.00
Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group. Crit Rev Oncol Hematol (2000) 1.00
Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg (2008) 1.00
Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol (2004) 0.98
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol (2006) 0.96
Age contrast in ovarian pathology. Cancer (1993) 0.95
Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. Ann Oncol (2006) 0.95
Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer (1996) 0.94
Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol (2007) 0.94
Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol (1993) 0.93
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol (2008) 0.90
National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer (1994) 0.90
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol (2008) 0.90
Patterns of care for women with ovarian cancer in the United States. J Clin Oncol (1997) 0.89
Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer (2007) 0.88
Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol (2004) 0.88
Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol (2008) 0.87
Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol (2002) 0.87
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol (2008) 0.86
Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol (2008) 0.86
An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol (2004) 0.84
Delayed diagnosis of gynecologic tumors in elderly women: relation to national medical practice patterns. Am J Med (1989) 0.84
Ovarian cancer debulking surgery: a survey of practice in Australia and New Zealand. Int J Gynecol Cancer (2011) 0.83
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer (2002) 0.82
Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: a population-based study from 1983 to 2007 in Niigata. J Obstet Gynaecol Res (2012) 0.81
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. Crit Rev Oncol Hematol (2009) 0.80
Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol (2002) 0.80
Ovarian cancer in older women. Semin Oncol (2008) 0.80
Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer (1993) 0.79
Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer (1993) 0.78
Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer (1993) 0.78
Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group studies. Cancer (1993) 0.78
The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. Gynecol Oncol (2010) 0.77
Elderly ovarian cancer: treatment with mitoxantrone-carboplatin. Gynecol Oncol (2001) 0.76
Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer (2000) 0.76
Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol (2002) 0.75
Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin? Gynecol Oncol (1999) 0.75
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol (2011) 4.07
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg (2008) 2.30
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol (2011) 1.76
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res (2010) 1.67
Has demand for clinical trial participants outpaced supply? J Natl Cancer Inst (2007) 1.39
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res (2007) 1.39
Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc (2007) 1.35
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol (2013) 1.16
Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol (2011) 1.16
Distress in older patients with cancer. J Clin Oncol (2009) 1.13
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol (2007) 1.11
Multicenter Evaluation of Rectal cancer ReImaging POst Neoadjuvant (MERRION) Therapy. Ann Surg (2015) 1.08
Chemotherapy options and outcomes in older adult patients with colorectal cancer. Crit Rev Oncol Hematol (2009) 1.06
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol (2012) 1.06
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol (2008) 1.05
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol (2011) 1.03
The translational imperative: making cell therapy simple and effective. Acta Biomater (2012) 0.99
Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol (2007) 0.98
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology . J Natl Compr Canc Netw (2014) 0.97
Unusual abdominal tumors, case 1. Pseudomyxoma peritonei: response to capecitabine. J Clin Oncol (2004) 0.97
Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc (2014) 0.97
NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw (2008) 0.96
A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist (2009) 0.96
Geriatric oncology: an overview. J Clin Oncol (2014) 0.96
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs (2010) 0.95
Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol (2007) 0.94
Short-term nutritional implications of total gastrectomy for malignancy, and the impact of parenteral nutritional support. Clin Nutr (2007) 0.94
Pharmacokinetics of chemotherapy in the older patient. Cancer Control (2007) 0.92
Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer (2011) 0.92
Toxicity of bevacizumab in combination with chemotherapy in older patients. Oncologist (2013) 0.90
Breast and ovarian cancer in the older woman. J Clin Oncol (2014) 0.88
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol (2009) 0.87
Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. Gynecol Oncol (2012) 0.87
Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. Gynecol Oncol (2011) 0.87
Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. Gynecol Oncol (2008) 0.86
Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters. Int J Gynecol Cancer (2013) 0.86
Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib. Am J Clin Oncol (2017) 0.85
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol (2009) 0.85
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging (2002) 0.85
New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat (2014) 0.85
Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist (2005) 0.83
Sorafenib-induced tuberculosis reactivation. Onkologie (2012) 0.82
Testicular cancer and platinum: a double-edged sword. J Clin Oncol (2014) 0.82
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res (2004) 0.81
Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer. Gynecol Oncol (2013) 0.80
Ovarian cancer in older women. Semin Oncol (2008) 0.80
Call for changes in clinical trial reporting of older patients with cancer. J Clin Oncol (2012) 0.80
Treatment of BRAF inhibitor-induced hyperkeratosis. Acta Oncol (2012) 0.80
Geriatric Assessment as a Predictor of Delirium and Other Outcomes in Elderly Patients With Cancer. Ann Surg (2015) 0.79
Chemotherapy for the elderly patient with colorectal cancer. Cancer J (2010) 0.79
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies. Int J Gynecol Cancer (2013) 0.79
Use of complementary medications among older adults with cancer. Cancer (2012) 0.79
Management of the elderly patient with gynecologic cancer: report of the 2011 workshop in geriatric gynecologic oncology. Int J Gynecol Cancer (2012) 0.79
Post irradiation olfactory neuroblastoma (esthesioneuroblastoma): a case report and up to date review. Acta Oncol (2009) 0.79
Thiolated hyaluronan-based hydrogels crosslinked using oxidized glutathione: an injectable matrix designed for ophthalmic applications. Acta Biomater (2013) 0.78
Effect of age on drug metabolism in women with breast cancer. Expert Opin Drug Metab Toxicol (2015) 0.78
Phyllodes tumor of the breast. Med Oncol (2010) 0.78
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Invest New Drugs (2011) 0.78
Lhermitte's phenomenon and platinum, beware of latency. Oncol Res Treat (2014) 0.78
Treatment of elderly cancer patients with chemotherapy. Cancer Invest (2005) 0.78
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer (2012) 0.77
Translocation renal cell carcinomas: an evolving entity and a member of the microphthalmia transcription factor-associated family of tumors. Clin Genitourin Cancer (2013) 0.77
CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer. Int J Gynecol Cancer (2013) 0.77
Surgical management of metastatic melanoma in the era of targeted systemic therapies. Melanoma Res (2015) 0.77
Juvenile polyposis syndrome presenting with familial gastric cancer and massive gastric polyposis. J Clin Oncol (2012) 0.77
Management of colorectal cancer in older patients. Oncology (Williston Park) (2006) 0.76
A case series of patients on chemotherapy with dyspnoea and pulmonary infiltrates. BMJ Case Rep (2013) 0.76
Intratumor heterogeneity and branched evolution. N Engl J Med (2012) 0.76
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Int J Gynecol Cancer (2016) 0.76
Identification of distinct phenotypes of locally advanced pancreatic adenocarcinoma. J Gastrointest Cancer (2013) 0.76
Hepatic arterial infusion: a treatment at the "end of an era"? J Clin Oncol (2008) 0.75
Immuno-nutrition in upper gastrointestinal surgery. Ann Surg (2009) 0.75
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection? Ann Surg (2009) 0.75
Resection of colorectal liver metastases: only for younger patients? Lancet Oncol (2010) 0.75
Senior adult oncology: three cases of advanced cancer in patients of advanced age. Semin Oncol (2012) 0.75
Reply to L.K. Mell et al. J Clin Oncol (2014) 0.75
Preoperative chemoradiotherapy for esophageal cancer. N Engl J Med (2012) 0.75
Treatment of advanced lung cancer in the elderly. Hosp Pract (1995) (2011) 0.75
Borderline resectable pancreatic adenocarcinoma, is conversion therapy realistic? Acta Oncol (2014) 0.75
Care of elderly women with ovarian cancer. Geriatr Nurs (2004) 0.75
A case of sarcoidosis in a patient with testicular cancer post stem cell transplant. Acta Oncol (2012) 0.75
Metastatic germ cell tumour following renal transplantation. Onkologie (2013) 0.75
Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis. Int J Gynecol Pathol (2016) 0.75
A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine. Cancer Invest (2007) 0.75
Prophylactic cranial irradiation: 5 years on. BMJ Support Palliat Care (2013) 0.75
High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Res (2015) 0.75
Unusual uterine recurrence of primary central nervous system lymphoma. Clin Adv Hematol Oncol (2006) 0.75